$EGRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in EAGLE PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in EAGLE PHARMACEUTICALS, INC.. Get notifications about new insider transactions in EAGLE PHARMACEUTICALS, INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 69.95 | 2,431 | 170,048 | 1,422,193 | 1.4 M to 1.4 M (-0.17 %) |
| Feb 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 68.52 | 5,260 | 360,415 | 1,424,624 | 1.4 M to 1.4 M (-0.37 %) |
| Feb 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 67.46 | 3,600 | 242,856 | 1,429,884 | 1.4 M to 1.4 M (-0.25 %) |
| Feb 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 66.03 | 5,367 | 354,383 | 1,433,484 | 1.4 M to 1.4 M (-0.37 %) |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | A | 86.15 | 15,000 | 1,292,250 | 15,000 | |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Option Exercise | A | 86.15 | 62,100 | 5,349,915 | 62,100 | |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Option Exercise | A | 86.15 | 180,000 | 15,507,000 | 180,000 | |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 87.02 | 2,773 | 241,306 | 1,438,851 | 1.4 M to 1.4 M (-0.19 %) |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 85.65 | 11,776 | 1,008,614 | 1,441,624 | 1.5 M to 1.4 M (-0.81 %) |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Director | Option Exercise | A | 86.15 | 15,000 | 1,292,250 | 15,000 | |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Option Exercise | A | 86.15 | 15,000 | 1,292,250 | 15,000 | |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | Graves Michael | Director | Option Exercise | A | 86.15 | 15,000 | 1,292,250 | 15,000 | |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | A | 86.15 | 15,000 | 1,292,250 | 15,000 | |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Option Exercise | A | 86.15 | 15,000 | 1,292,250 | 15,000 | |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | Hepner Adrian | Executive VP | Option Exercise | A | 86.15 | 62,100 | 5,349,915 | 62,100 | |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | RIGGS DAVID E | Chief Financial Off ... | Option Exercise | A | 86.15 | 62,100 | 5,349,915 | 62,100 | |
| Dec 23 2015 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Sell | S | 93.76 | 3,225 | 302,360 | 16,374 | 19.6 K to 16.4 K (-16.45 %) |
| Dec 23 2015 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Sell | S | 42.00 | 9,800 | 411,600 | 19,599 | 29.4 K to 19.6 K (-33.33 %) |
| Dec 02 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 91.46 | 1,300 | 118,898 | 1,453,400 | 1.5 M to 1.5 M (-0.09 %) |
| Dec 02 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 90.99 | 3,700 | 336,663 | 1,454,700 | 1.5 M to 1.5 M (-0.25 %) |
| Dec 02 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 88.80 | 1,500 | 133,200 | 1,458,400 | 1.5 M to 1.5 M (-0.10 %) |
| Dec 02 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 87.85 | 4,744 | 416,760 | 1,459,900 | 1.5 M to 1.5 M (-0.32 %) |
| Dec 02 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 86.92 | 2,806 | 243,898 | 1,464,644 | 1.5 M to 1.5 M (-0.19 %) |
| Nov 03 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 65.50 | 7,626 | 499,503 | 1,467,450 | 1.5 M to 1.5 M (-0.52 %) |
| Nov 03 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 64.07 | 11,713 | 750,452 | 1,475,076 | 1.5 M to 1.5 M (-0.79 %) |
| Oct 05 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 68.50 | 1,065 | 72,953 | 1,486,789 | 1.5 M to 1.5 M (-0.07 %) |
| Oct 05 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 69.27 | 8,235 | 570,438 | 1,487,854 | 1.5 M to 1.5 M (-0.55 %) |
| Oct 05 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 70.28 | 7,027 | 493,858 | 1,496,089 | 1.5 M to 1.5 M (-0.47 %) |
| Oct 05 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 72.67 | 1,548 | 112,493 | 1,503,116 | 1.5 M to 1.5 M (-0.10 %) |
| Oct 05 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 74.36 | 3 | 223 | 1,504,664 | 1.5 M to 1.5 M (0.00 %) |
| Sep 03 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 75.12 | 49 | 3,681 | 1,504,667 | 1.5 M to 1.5 M (0.00 %) |
| Sep 03 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 76.09 | 1,878 | 142,897 | 1,504,716 | 1.5 M to 1.5 M (-0.12 %) |
| Sep 03 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 76.88 | 11,792 | 906,569 | 1,506,594 | 1.5 M to 1.5 M (-0.78 %) |
| Sep 03 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 77.93 | 2,526 | 196,851 | 1,518,386 | 1.5 M to 1.5 M (-0.17 %) |
| Aug 04 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 95.39 | 2,342 | 223,403 | 1,520,912 | 1.5 M to 1.5 M (-0.15 %) |
| Aug 04 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 96.36 | 10,658 | 1,027,005 | 1,523,254 | 1.5 M to 1.5 M (-0.69 %) |
| Jul 02 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 77.58 | 3,710 | 287,822 | 1,533,912 | 1.5 M to 1.5 M (-0.24 %) |
| Jul 02 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 78.98 | 6,015 | 475,065 | 1,537,622 | 1.5 M to 1.5 M (-0.39 %) |
| Jul 02 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 80.28 | 1,483 | 119,055 | 1,543,637 | 1.5 M to 1.5 M (-0.10 %) |
| Jul 02 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 81.50 | 4,502 | 366,913 | 1,545,120 | 1.5 M to 1.5 M (-0.29 %) |
| Jul 02 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 42.00 | 120,000 | 5,040,000 | 1,549,622 | 1.7 M to 1.5 M (-7.19 %) |
| Jul 02 2015 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Management LLC | 10% Owner | Sell | J | 0.00 | 2,970 | 0 | 59,061 | 62 K to 59.1 K (-4.79 %) |
| Jun 18 2015 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Option Exercise | M | 4.42 | 1,400 | 6,188 | 20,517 | |
| Jun 18 2015 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Option Exercise | M | 8.78 | 2,730 | 23,969 | 2,730 | |
| Jun 18 2015 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Option Exercise | M | 8.78 | 5,850 | 51,363 | 1,950 | |
| Jun 18 2015 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Sell | S | 81.60 | 1,400 | 114,240 | 0 | 1.4 K to 0 (-100.00 %) |
| Jun 18 2015 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Buy | M | 4.42 | 1,400 | 6,188 | 1,400 | 0 to 1.4 K |
| Jun 18 2015 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Sell | S | 81.60 | 2,730 | 222,768 | 0 | 2.7 K to 0 (-100.00 %) |
| Jun 18 2015 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Buy | M | 8.78 | 2,730 | 23,969 | 2,730 | 0 to 2.7 K |
| Jun 18 2015 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Sell | S | 81.60 | 5,850 | 477,360 | 0 | 5.9 K to 0 (-100.00 %) |
| Jun 18 2015 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Buy | M | 8.78 | 5,850 | 51,363 | 5,850 | 0 to 5.9 K |
| May 07 2015 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Management LLC | 10% Owner | Sell | J | 0.00 | 9,903 | 0 | 62,031 | 71.9 K to 62 K (-13.77 %) |
| Apr 22 2015 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Option Exercise | A | 59.31 | 10,000 | 593,100 | 10,000 | |
| Apr 22 2015 | EGRX | EAGLE PHARMACEUTIC ... | Graves Michael | Director | Option Exercise | A | 59.31 | 10,000 | 593,100 | 10,000 | |
| Apr 22 2015 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Option Exercise | A | 59.31 | 10,000 | 593,100 | 10,000 | |
| Apr 22 2015 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | A | 59.31 | 10,000 | 593,100 | 10,000 | |
| Apr 22 2015 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | A | 59.31 | 10,000 | 593,100 | 10,000 | |
| Apr 22 2015 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Director | Option Exercise | A | 59.31 | 15,000 | 889,650 | 15,000 | |
| Apr 10 2015 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Director | Option Exercise | A | 46.81 | 10,000 | 468,100 | 10,000 | |
| Apr 10 2015 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Director | Option Exercise | A | 46.81 | 10,000 | 468,100 | 10,000 | |
| Mar 18 2015 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | A | 46.09 | 5,000 | 230,450 | 5,000 | |
| Mar 18 2015 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | A | 46.09 | 5,000 | 230,450 | 5,000 | |
| Mar 17 2015 | EGRX | EAGLE PHARMACEUTIC ... | Graves Michael | Director | Option Exercise | A | 46.09 | 5,000 | 230,450 | 5,000 | |
| Mar 17 2015 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Option Exercise | A | 46.09 | 5,000 | 230,450 | 5,000 | |
| Mar 17 2015 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Option Exercise | A | 46.09 | 125,000 | 5,761,250 | 125,000 | |
| Mar 17 2015 | EGRX | EAGLE PHARMACEUTIC ... | RIGGS DAVID E | Chief Financial Off ... | Option Exercise | A | 46.09 | 56,286 | 2,594,222 | 56,286 | |
| Mar 17 2015 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Option Exercise | A | 46.09 | 5,000 | 230,450 | 5,000 | |
| Mar 17 2015 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Option Exercise | A | 46.09 | 71,286 | 3,285,572 | 71,286 | |
| Aug 27 2014 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Option Exercise | A | 12.63 | 40,000 | 505,200 | 40,000 | |
| Aug 27 2014 | EGRX | EAGLE PHARMACEUTIC ... | BRUINENBERG PAUL | Chief Medical Offic ... | Option Exercise | A | 12.63 | 10,000 | 126,300 | 10,000 | |
| Aug 27 2014 | EGRX | EAGLE PHARMACEUTIC ... | RIGGS DAVID E | Chief Financial Off ... | Option Exercise | A | 12.63 | 25,000 | 315,750 | 25,000 | |
| Aug 27 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Option Exercise | A | 12.63 | 75,000 | 947,250 | 75,000 | |
| May 02 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | A | 12.67 | 4,680 | 59,296 | 4,680 | |
| May 02 2014 | EGRX | EAGLE PHARMACEUTIC ... | RIGGS DAVID E | Chief Financial Off ... | Option Exercise | A | 12.67 | 17,608 | 223,093 | 17,608 | |
| May 02 2014 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Option Exercise | A | 12.67 | 4,680 | 59,296 | 4,680 | |
| May 02 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | A | 12.67 | 4,680 | 59,296 | 4,680 | |
| May 02 2014 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | Chief Scientific Of ... | Option Exercise | A | 12.67 | 17,905 | 226,856 | 17,905 | |
| May 02 2014 | EGRX | EAGLE PHARMACEUTIC ... | Graves Michael | Director | Option Exercise | A | 12.67 | 4,680 | 59,296 | 4,680 | |
| May 02 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Option Exercise | A | 12.67 | 4,680 | 59,296 | 4,680 | |
| May 02 2014 | EGRX | EAGLE PHARMACEUTIC ... | BRUINENBERG PAUL | Chief Medical Offic ... | Option Exercise | A | 12.67 | 19,323 | 244,822 | 19,323 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | X | 0.00 | 1,614 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | C | 0.00 | 9,359 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | C | 0.00 | 62,575 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | X | 0.00 | 98,368 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | C | 0.00 | 569,538 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | C | 0.00 | 850,520 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | C | 0.00 | 1,028,613 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Option Exercise | C | 0.00 | 1,927,986 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | X | 0.00 | 357 | 0 | 72,291 | 71.9 K to 72.3 K (+0.50 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | C | 0.00 | 9,359 | 0 | 71,934 | 62.6 K to 71.9 K (+14.96 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | C | 0.00 | 62,575 | 0 | 62,575 | 0 to 62.6 K |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | P | 15.00 | 333,333 | 4,999,995 | 4,770,828 | 4.4 M to 4.8 M (+7.51 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | X | 0.00 | 21,837 | 0 | 4,437,495 | 4.4 M to 4.4 M (+0.49 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | C | 0.00 | 569,538 | 0 | 4,415,658 | 3.8 M to 4.4 M (+14.81 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | C | 0.00 | 850,520 | 0 | 3,846,120 | 3 M to 3.8 M (+28.39 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | C | 0.00 | 1,028,613 | 0 | 2,995,600 | 2 M to 3 M (+52.29 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | SCHREIBER ALAIN | Director | Buy | C | 0.00 | 1,927,986 | 0 | 1,966,987 | 39 K to 2 M (+4,943.43 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | X | 0.00 | 1,614 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | C | 0.00 | 9,359 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | C | 0.00 | 62,575 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | X | 0.00 | 98,368 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | C | 0.00 | 569,538 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | C | 0.00 | 850,520 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | C | 0.00 | 1,028,613 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Option Exercise | C | 0.00 | 1,927,986 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | X | 0.00 | 357 | 0 | 72,291 | 71.9 K to 72.3 K (+0.50 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | C | 0.00 | 9,359 | 0 | 71,934 | 62.6 K to 71.9 K (+14.96 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | C | 0.00 | 62,575 | 0 | 62,575 | 0 to 62.6 K |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | P | 15.00 | 333,333 | 4,999,995 | 4,770,828 | 4.4 M to 4.8 M (+7.51 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | X | 0.00 | 21,837 | 0 | 4,437,495 | 4.4 M to 4.4 M (+0.49 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | C | 0.00 | 569,538 | 0 | 4,415,658 | 3.8 M to 4.4 M (+14.81 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | C | 0.00 | 850,520 | 0 | 3,846,120 | 3 M to 3.8 M (+28.39 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | C | 0.00 | 1,028,613 | 0 | 2,995,600 | 2 M to 3 M (+52.29 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Moorin Jay | Director | Buy | C | 0.00 | 1,927,986 | 0 | 1,966,987 | 39 K to 2 M (+4,943.43 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | X | 0.00 | 1,614 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | C | 0.00 | 9,359 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | C | 0.00 | 62,575 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | X | 0.00 | 98,368 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | C | 0.00 | 569,538 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | C | 0.00 | 850,520 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | C | 0.00 | 1,028,613 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Option Exercise | C | 0.00 | 1,927,986 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | X | 0.00 | 357 | 0 | 72,291 | 71.9 K to 72.3 K (+0.50 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | C | 0.00 | 9,359 | 0 | 72,291 | 62.9 K to 72.3 K (+14.87 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | C | 0.00 | 62,575 | 0 | 71,934 | 9.4 K to 71.9 K (+668.61 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | P | 15.00 | 333,333 | 4,999,995 | 4,770,828 | 4.4 M to 4.8 M (+7.51 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | X | 0.00 | 21,837 | 0 | 4,437,495 | 4.4 M to 4.4 M (+0.49 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | C | 0.00 | 569,538 | 0 | 4,415,658 | 3.8 M to 4.4 M (+14.81 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | C | 0.00 | 850,520 | 0 | 3,846,120 | 3 M to 3.8 M (+28.39 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | C | 0.00 | 1,028,616 | 0 | 2,995,600 | 2 M to 3 M (+52.29 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Associates IV LLC | 10% Owner | Buy | C | 0.00 | 1,927,986 | 0 | 1,966,987 | 39 K to 2 M (+4,943.43 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Option Exercise | C | 0.00 | 2,887 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Option Exercise | C | 0.00 | 8,572 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Option Exercise | C | 0.00 | 8,580 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Buy | C | 0.00 | 2,887 | 0 | 29,399 | 26.5 K to 29.4 K (+10.89 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Buy | C | 0.00 | 8,572 | 0 | 26,512 | 17.9 K to 26.5 K (+47.78 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Buy | C | 0.00 | 8,580 | 0 | 17,940 | 9.4 K to 17.9 K (+91.67 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Option Exercise | C | 0.00 | 1,443 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Option Exercise | C | 0.00 | 8,571 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Buy | C | 0.00 | 1,443 | 0 | 19,374 | 17.9 K to 19.4 K (+8.05 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Buy | C | 0.00 | 8,571 | 0 | 17,931 | 9.4 K to 17.9 K (+91.57 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Option Exercise | X | 0.00 | 3,438 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Option Exercise | C | 0.00 | 25,376 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Option Exercise | C | 0.00 | 171,109 | 0 | 0 | |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Buy | X | 0.00 | 763 | 0 | 1,669,622 | 1.7 M to 1.7 M (+0.05 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Buy | C | 0.00 | 25,376 | 0 | 1,668,859 | 1.6 M to 1.7 M (+1.54 %) |
| Feb 20 2014 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Buy | C | 0.00 | 171,109 | 0 | 1,643,483 | 1.5 M to 1.6 M (+11.62 %) |